Reply

Journal of the American College of Cardiology

Volumn 61, Issue 5, 2013, Pages 596-

  Lip, Gregory Y H ^a   Larsen, Torben Bjerregaard ^b   Skjøth, Flemming ^b   Rasmussen, Lars Hvilsted ^b  

^a CITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN;

BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; SAMPLE SIZE; STUDY DESIGN; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; FEMALE; HEMORRHAGE; HUMANS; MALE; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; STROKE; THIOPHENES;

EID: 84873098867     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.10.034     Document Type: Letter

References (5)

1. G.Y. Lip, T.B. Larsen, F. Skjøth, L.H. Rasmussen Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J Am Coll Cardiol 60 2012 738 746
2. F. Skjøth, T.B. Larsen, L.H. Rasmussen Indirect comparison studies - are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation Thromb Haemost 108 2012 405 406
3. S. Mantha, J. Ansell An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation Thromb Haemost 108 2012 476 484
4. J. Harenberg, S. Marx, H.C. Diener Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Int Angiol 31 2012 33 39
5. A.R. Kansal, M. Sharma, C. Bradley-Kennedy Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Thromb Haemost 108 2012 672 682